Trials / Not Yet Recruiting
Not Yet RecruitingNCT07221968
Melatonin for the Treatment of DEE-SWAS
Melatonin for the Treatment of Developmental/Epileptic Encephalopathy With Spike Wave Activation In Sleep (DEE-SWAS; Formerly ESES)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Academic / Other
- Sex
- All
- Age
- 5 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to learn if melatonin, a naturally produced substance, can help to treat some of the symptoms of DEE-SWAS, a type of epilepsy that causes children to lose skills and development. It will look at doses of melatonin that are higher than most people use. The study will look at the safety of melatonin in patients with DEE-SWAS The study will look at the ways melatonin affects abnormal brain activity on a study called an EEG. The study will look at the ways melatonin affects normal brain activity that occurs in sleep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melatonin | Melatonin will be used in single fixed dose as described |
Timeline
- Start date
- 2026-07-01
- Primary completion
- 2028-07-01
- Completion
- 2028-12-30
- First posted
- 2025-10-29
- Last updated
- 2025-10-30
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07221968. Inclusion in this directory is not an endorsement.